| II-33 Xia Li Population Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Wednesday 15:10-16:40 |
| II-33 Xia Li Population Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Wednesday 15:10-16:40 |